Top Ten: Weekend roundup: Campbell in the soup | New cancer treatment | Exposing bad investment advice

MarketWatch rounded up 10 of its most interesting topics over the past week.

1. The trend for Campbell is anything but m’m m’m good

Campbell Soup Co. CPB, -1.73% had a rough quarter, but the company is facing a dire long-term problem.

2. New cancer treatment and its investment implications

Novartis AG NVS, -0.57% received FDA approval for the first cancer gene therapy available in the U.S. Emma Court explained how important this is for young people suffering from a type of acute lymphoblastic leukemia (ALL), and she interviewed Janney analyst Paul Knight, who made recommendations for investors on how to play “a potential decade-long growth cycle” for gene therapy.

>>> Original Source <<<